Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.

Mease, Philip J; Helliwell, Philip S; Hjuler, Kasper Fjellhaugen; Raymond, Kyle; McInnes, Iain

Mease, Philip J; Helliwell, Philip S; Hjuler, Kasper Fjellhaugen; Raymond, Kyle; McInnes, Iain.

Affiliation

Mease PJ; Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA pmease@philipmease.com.
Helliwell PS; Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Hjuler KF; Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Raymond K; Medical Department, Leo Pharma, Ballerup, Denmark.
McInnes I; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Ann Rheum Dis ; 80(2): 185-193, 2021 02.

Article in En | MEDLINE | ID: mdl-33106286

Subject(s)

Antibodies, Monoclonal, Humanized/administration & dosage; Arthritis, Psoriatic/drug therapy; Receptors, Interleukin-17/antagonists & inhibitors; Adolescent; Adult; Arthritis, Psoriatic/immunology; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Severity of Illness Index; Treatment Outcome; Young Adult

Key words

DMARDs (biologic); autoimmune diseases; psoriatic arthritis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Arthritis, Psoriatic / Receptors, Interleukin-17 / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google